i The accompanying notes are an integral part of these condensed consolidated financial statements. | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------|-------|------------------------------|-------|-------|--------| | Assets | | MARCH 31, 2024 (Unaudited) | | 2023 | | | Current assets: | | | | | | | Cash and cash equivalents | $ | 25,713 | $ | | 35,413 | | Prepaid expenses and other current assets | | 1,423 | | | 1,384 | | Total current assets | | 27,1 ...

▪ Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CAN-2409 for the treatment of pancreatic cancer. ▪ Received Fast Track Designation from the FDA for CAN-3110 for the treatment of patients with rHGG to improve OS. ▪ Presented preclinical data at the AACR Annual Meeting unveiling the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures (TLS), being developed as a novel therapeu ...

NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. Program Updates CAN-2409 – Pancreatic Cancer In early April, announced positive updated survival data, from the ongoing randomized phase 2 clinical trial ...

KanawatTH/iStock via Getty Images Candel Therapeutics, Inc. (NASDAQ:CADL) was able to report positive interim results from its phase 2 randomized study using CAN-2409 plus valacyclovir [prodrug] together with standard of care [SOC] chemoradiation, following by resection in patients with borderline respectable pancreatic ductal adenocarcinoma [PDAC]. Not only that, but it also achieved Orphan Drug Designation [ODD] of CAN-2409 for the treatment of this patient population. Both of these events have led to ...

Candel Therapeutics, Inc. (CADL) announced that the FDA has granted orphan drug designation to its lead investigational adenovirus immunotherapy candidate, CAN-2409, for the treatment of pancreatic ductal adenocarcinoma (PDAC). Shares of the company rallied 42.8% on Apr 12, following the news.The FDA grants the orphan drug designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The orphan drug designation will grant Candel market e ...

NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. "We recently reported data from the ph ...

First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery PlatformDelivery of two unique payload combinations, predicted in silico using the enLIGHTEN™ Advanced Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in preclinical models of cancerThis presentation accelerat ...

Candel Therapeutics, Inc.’s (CADL) shares skyrocketed 280.9% on Apr 5, after the company announced positive interim data from the phase II study evaluating its lead candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notable improvements in estimated median ove ...

Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer.CAN-2409 data sends Candel Therapeutics stock up Copy link to section Patients on CAN-2409 showed a meaningful increase in survival in a Phase II study, as per the biotechnology company. No new safety concerns were discovered in the clinical trial either. Garrett Nichols – the chief medical officer of $CADL said in a press release today:“CA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | |-----------------------------------------------------------------------------------------------------|------------------------------------------| | CANDEL (Exact name of Registrant as specified in its Charter) \nDelaware | THERAPEUTICS, INC. \n52-2214851 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 117 Kendrick St, Suite 450 Needham, MA (Address of principal ...